Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. Lancet 2019;393:2404–15

Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(19)30723-8 ◽

2019 ◽

Vol 393 (10189) ◽

pp. 2404-2415 ◽

Cited By ~ 233

Author(s):

Brian I Rini ◽

Thomas Powles ◽

Michael B Atkins ◽

Bernard Escudier ◽

David F McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

A Randomised Controlled Trial of IFN-α, IL-2 and 5FU Versus IFN-α Alone in Metastatic Renal Cell Carcinoma (ISRCTN 46518965)

UroOncology ◽

10.1080/1561095021000018704 ◽

2002 ◽

Vol 2 (2) ◽

pp. 51-53

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70465-0 ◽

2013 ◽

Vol 14 (13) ◽

pp. 1287-1294 ◽

Cited By ~ 243

Author(s):

Thomas E Hutson ◽

Vladimir Lesovoy ◽

Salman Al-Shukri ◽

Viktor P Stus ◽

Oleg N Lipatov ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30408-9 ◽

2016 ◽

Vol 17 (11) ◽

pp. 1599-1611 ◽

Cited By ~ 90

Author(s):

Brian I Rini ◽

Arnulf Stenzl ◽

Romauld Zdrojowy ◽

Mikhail Kogan ◽

Mikhail Shkolnik ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30735-1 ◽

2020 ◽

Vol 21 (1) ◽

pp. 95-104 ◽

Cited By ~ 22

Author(s):

Brian I Rini ◽

Sumanta K Pal ◽

Bernard J Escudier ◽

Michael B Atkins ◽

Thomas E Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

The Oncologist ◽

10.1634/theoncologist.2018-0299 ◽

2018 ◽

Vol 24 (2) ◽

pp. 202-210 ◽

Cited By ~ 8

Author(s):

Toni K. Choueiri ◽

M. Dror Michaelson ◽

Edwin M. Posadas ◽

Guru P. Sonpavde ◽

David F. McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Dose Escalation ◽

Renal Cell ◽

Open Label ◽

Dose Escalation Study ◽

Phase Ib ◽

Open Label Phase

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer ◽

10.1002/cncr.33033 ◽

2020 ◽

Vol 126 (18) ◽

pp. 4156-4167 ◽

Cited By ~ 6

Author(s):

Robert J. Motzer ◽

Bernard Escudier ◽

Saby George ◽

Hans J. Hammers ◽

Sandhya Srinivas ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Long Term Follow Up

Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate-to-severe anaemia in India: a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Global Health ◽

10.1016/s2214-109x(19)30427-9 ◽

2019 ◽

Vol 7 (12) ◽

pp. e1706-e1716 ◽

Cited By ~ 6

Author(s):

Sutapa B Neogi ◽

Niveditha Devasenapathy ◽

Ranjana Singh ◽

Himanshu Bhushan ◽

Duru Shah ◽

...

Keyword(s):

Pregnant Women ◽

Controlled Trial ◽

Intravenous Iron ◽

Severe Anaemia ◽

Iron Sucrose ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Faculty Opinions recommendation of Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717950273.793455532 ◽

2012 ◽

Author(s):

Alexander Eggermont

Keyword(s):

Metastatic Melanoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽